
Velasof Tablet
Salt Composition: Sofosbuvir and Velpatasvir
Expiry Date: 01/2028
Inclusive of all taxes
28 tablet

Velasof Tablet
28 tablet
Sofosbuvir/Velpatasvir
Salt Composition
Sofosbuvir and Velpatasvir
Storage
Below 25°C
Expiry Date
01/2028
Marketer
Hetero Health Care
Brand
velasof

Myhep All Tablet
28 tablet
Sofosbuvir and Velpatasvir
Salt Composition
Sofosbuvir and Velpatasvir
Storage
Below 25°C
Expiry Date
01/2028
Marketer
mylan pharmaceuticals
Brand
myhep all
5966.png&w=1920&q=75)
MAGIC DEALS
Enquire
Apply Promo Code
Available CouponsVelasof Tablet
Inclusive of all taxes
In Stock
Authorized
Global Reach
Verified Logistics
The price displayed is inclusive of applicable taxes. Any additional fee (such as shipping fee, handling and/or platform fee etc.) will be clearly disclosed before you complete your purchase.
About The Product
Chronic hepatitis C virus (HCV) infection
Velasof Tablet is a viral treatment medication that is used for treating chronic hepatitis C virus infections. This tablet is comprised of two constituents that are sofobuvir and velpatasvir of strength 400mg and 100mg respectively. It helps protect the liver, reduces the risk of cirrhosis and liver cancer, and can cure more than 95 percent of patients. The usual length of treatment is 12 weeks. One tablet is taken each day, with or without food. Side effects can include headache, tiredness, nausea, and sleep problems. Patients should avoid alcohol and tell their doctor about any other health problems or medications they are taking, especially if they have kidney or severe liver problems.
Overview
The formation of Velasof Tablets is made up of both Sofosbuvir (400 mg) and Velpatasvir (100 mg). This pair works unitedly in healing chronic hepatitis C infections.
They function to stop viral reproduction in the body and help to clear the virus from the body naturally. As per the doctor's advice, this medicine is consumed once daily.
Common side effects of Velasof Tablets include headache, tiredness, nausea, and weakness.
Quick Product Facts
Item | Detail |
Generic name | Sofosbuvir and velpatasvir fixed-dose combination |
Strength | Sofosbuvir 400 mg and velpatasvir 100 mg in each tablet |
Maker and approval | Hetero. DCGI approval was announced on 5 May 2017. Reference product: Gilead's Epclusa |
Pack | 28 tablets |
Drug class | NS5B nucleotide polymerase inhibitor plus NS5A inhibitor |
Usual dose | One tablet once daily, with or without food |
Boxed warning | Risk of hepatitis B virus reactivation in people infected with both viruses |
Storage | Keep at room temperature (20°C to 25°C / below 25°C). Do not freeze. |
Prescription status | Prescription medicine. |
Price control | The price of the Velasof tablet is not fixed; it varies depending on the location, availability, and manufacturing. |
Price | The price of the tablet is not constant; it varies depending upon the pharmacy, location, and manufacturing. |
Velasof Tablet Uses and Indications
The uses of the Velasof tablet are several. It is used for the treatment of chronic hepatitis C of genotypes 1, 2, 3, 4, 5, or 6. It covers adults and children aged 3 and older. This includes people:
Without cirrhosis or with compensated cirrhosis (Child-Pugh A), taking the tablets alone;
With decompensated cirrhosis (Child-Pugh B or C), taking the tablets together with ribavirin.
Velasof tablet does not treat hepatitis B, HIV, or liver cancer. Velasof 400/100 mg suits only adults and children who weigh at least 30 kg.
How Velasof Tablet Works
Sofosbuvir present in the Velasof tablet is a prodrug. The body turns it into an active form that is built into the virus's genetic material and stops the copying enzyme, NS5B, from working. Velpatasvir present in Velasof tablet blocks a second viral protein, NS5A, that the virus needs to multiply. Together they stop the virus from replicating across all six genotypes.
Sofosbuvir 400mg reaches its peak within 0.5 to 1 hour, and velpatasvir 100mg at about 3 hours. The main breakdown of sofosbuvir has a half-life of about 25 hours, and velpatasvir about 15 hours, so one tablet a day is enough. Meals raise exposure somewhat, but the velasof tablet can be taken with or without food.
Clinical Evidence for Velasof Tablet
12 weeks of the combination cleared the virus in about 95% to 99% of people in the main trials. The lowest rates were in genotype 3 with cirrhosis and in decompensated cirrhosis.
Study | Setting | Result (no virus 12 weeks after treatment) |
ASTRAL-1 | 624 adults with genotypes 1, 2, 4, 5, or 6, 12 weeks, vs placebo | 99% overall. Genotype 1a 98%, 1b 99%, 2 100%, 4 100%, 5 97%, 6 100%. No placebo patient was cured. |
ASTRAL-2 | Genotype 2: 134 on the combination vs 132 on sofosbuvir plus ribavirin | 99% vs 94%. |
ASTRAL-3 | Genotype 3: 277 on the combination for 12 weeks vs 275 on sofosbuvir plus ribavirin for 24 weeks | 95% vs 80%. With compensated cirrhosis: 93% if new to treatment, 89% if treated before. |
ASTRAL-4 | 87 people with decompensated cirrhosis, combination plus ribavirin, 12 weeks | 94% overall. Genotype 1: 96%. Genotype 3: 85%. |
ASTRAL-5 | 106 people with hepatitis C and HIV | 95%. |
Other groups | Liver transplant (79); dialysis (59); people who inject drugs (103); children 12 to 17 (102) | 96%; 95%; 94%; 93% in genotype 1 and 100% in genotypes 2, 3, 4, and 6. |
Genotype 3 with cirrhosis and the NS5A variant Y93H is the hardest case: 6 of 15 such people (40%) had treatment failure. The efficacy is not established in people who failed earlier treatment that included an NS5A inhibitor.
Velasof Tablet Side Effects
Most people have mild effects. In ASTRAL-1, 0.2% stopped treatment because of side effects, and many effects were as common on placebo as on treatment.
Effect | 12 weeks alone (ASTRAL-1) | With ribavirin, decompensated (ASTRAL-4) |
Headache | 22% | 11% |
Fatigue | 15% | 32% |
Nausea | 9% | 15% |
Insomnia | 5% | 11% |
With ribavirin, hemoglobin fell below 10 g/dL in 23% of people and below 8.5 g/dL in 7%, and 17% had to stop ribavirin. Rash occurred in 2% on the combination alone and 5% with ribavirin.
Serious side effects
Serious effects are rare, but each needs quick action.
Hepatitis B reactivation: in people carrying hepatitis B as well, treatment can wake the virus. Some cases caused fulminant hepatitis, liver failure, and death.
Slow heartbeat with amiodarone: serious symptomatic bradycardia, some needing a pacemaker, and one fatal cardiac arrest, reported with sofosbuvir regimens.
Skin and swelling: skin rashes, sometimes with blisters, and angioedema were reported after approval.
Blood sugar and clotting tests: as the liver recovers, diabetic patients had serious low blood sugar, and INR can change in people on warfarin.
Lab changes: isolated lipase rises above 3 times normal in 3% to 6%, and creatine kinase rises in 1% to 2%, without symptoms.
Critical Safety Warning
Call your local emergency number now for:
The boxed warning says to test everyone for current or past hepatitis B (HBsAg and anti-HBc) before starting. Reactivation can occur even in people who have cleared it. The only contraindication is that the combination with ribavirin cannot be used where ribavirin is contraindicated, which includes pregnancy and men whose partners are pregnant. |
Velasof Tablet Dosage and How To Take It
One velasof tablet once a day for 12 weeks, with or without food. People with decompensated cirrhosis also take ribavirin.
Who | Regimen |
Adults with no cirrhosis or compensated cirrhosis (Child-Pugh A) | One tablet (400 mg + 100 mg) once daily for 12 weeks |
Adults, decompensated cirrhosis (Child-Pugh B or C) | One tablet once daily plus ribavirin for 12 weeks |
Liver transplant, no cirrhosis or compensated cirrhosis | One tablet once daily for 12 weeks |
Hepatitis C with HIV | One tablet once daily for 12 weeks; antiretroviral interactions must be checked. |
Kidney problems, including dialysis | No dose change |
Children 3 and older | Weight-based: under 17 kg, 150/37.5 mg pellets; 17 to under 30 kg, 200/50 mg; 30 kg or more, 400/100 mg tablet |
Ribavirin: 1,000 mg a day if under 75 kg and 1,200 mg if 75 kg or more, split into two doses and taken with food. The dose is lowered by hemoglobin and kidney function.
Before the first tablet: test for hepatitis B (HBsAg and anti-HBc).
Acid-lowering medicines: separate antacids by 4 hours. Famotidine-type tablets can be taken together or 12 hours apart, up to a dose of famotidine 40 mg twice daily. Omeprazole and other proton-pump inhibitors are not recommended.
Length of treatment: 12 weeks. Do not stop early, even if you feel well.
Food and drink: the tablet can be taken with or without food.
For pharmacists and prescribers
Dispensing check: confirm hepatitis B status is recorded, then check for amiodarone, rifampicin, anticonvulsants, St. John's wort, efavirenz, acid-lowering medicines, statins, and warfarin.
Amiodarone: if no alternative exists, the label advises inpatient cardiac monitoring for the first 48 hours, then daily pulse checks every at least 2 weeks.
Velasof Tablet Missed Dose
- Call your doctor or pharmacist for advice, and do not take two tablets to catch up.
- In the trials, one treatment failure was consistent with missed doses, so tell your doctor if you miss tablets.
Safety Advice for Velasof Tablet
Test before treatment and monitor during and after therapy.
Avoid amiodarone unless no alternative; monitor heart function.
Consult a doctor; the ribavirin combination is contraindicated during pregnancy.
Discuss potential risks and benefits with your doctor.
Monitor blood glucose and INR regularly.
No dose adjustment is generally required; monitor liver function in decompensated cirrhosis.
No dose adjustment is generally required.
No dose adjustment required; monitor for possible reinfection.
Monitoring During Velasof Treatment
Check | Guidance | Why |
Hepatitis B tests (HBsAg, anti-HBc) | Before starting | Reactivation risk |
Liver tests and hepatitis flare signs | During treatment and follow-up if hepatitis B is present | Reactivation |
Heart rate if on amiodarone | Inpatient monitoring for 48 hours, then daily pulse for at least 2 weeks | Slow heartbeat |
Blood sugar in diabetes | Frequent monitoring and dose changes as needed | Low sugar |
INR on warfarin | Frequent monitoring | Clotting changes |
Hemoglobin and kidney function with ribavirin | Adjust ribavirin by results. | Anemia |
Liver tests with direct bilirubin in decompensated cirrhosis | As clinically indicated | Safety in advanced disease |
HCV RNA 12 weeks after the last tablet | The trials' cure test (SVR12) | Confirm cure |
Velasof Tablet Fact Box
Item | Detail |
Molecules | Sofosbuvir, molecular weight 529.45; velpatasvir, 883.0 |
Protein binding | Sofosbuvir 61% to 65%; velpatasvir above 99.5% |
Elimination | Sofosbuvir mainly as its metabolite in urine (about 80%); velpatasvir mainly in feces (about 94%) |
Heart rhythm (QT) | No clinically relevant QT prolongation at 3 times (sofosbuvir) and 5 times (velpatasvir) of the dose |
Boxed warning | Hepatitis B reactivation |
Contraindication | Combination with ribavirin where ribavirin is contraindicated |
Overdose | No antidote. Support and monitoring. Dialysis removes the main sofosbuvir metabolite but not velpatasvir. |
Resistance | Not established after failure of regimens that include an NS5A inhibitor |
Velasof Tablet Drug Interactions
Tell your team about every medicine and herbal product you take.
Drug / Class | Potential Interaction or Risk | What To Do |
Rifampicin, rifabutin, rifapentine | Reduced antiviral effectiveness | Avoid combination. |
Carbamazepine, phenytoin, phenobarbital | Reduced medicine levels | Avoid combination. |
St. John's wort | Reduced antiviral effectiveness | Avoid use. |
Efavirenz, tipranavir/ritonavir | Significant drug interactions | Avoid combinations. |
Amiodarone | Risk of serious slow heart rate | Avoid combinations. |
Antacids | Reduced drug absorption | Separate by 4 hours |
Famotidine and PPIs | May reduce velpatasvir absorption | Follow recommended dosing. |
Rosuvastatin, atorvastatin | Increased risk of muscle damage | Monitor for muscle symptoms. |
Digoxin | Increased digoxin levels | Monitor blood levels. |
Tenofovir DF | Increased kidney-related risks | Monitor kidney function. |
Warfarin | Changes in INR | Monitor INR |
Diabetes medicines | Risk of low blood sugar | Monitor glucose levels. |
Other listed medicines (methadone, dolutegravir, cyclosporine, and oral contraceptives) | No significant interaction generally expected | Routine monitoring |
FAQs About Velasof Tablet
Velasof tablet treats chronic hepatitis C caused by genotypes 1 to 6 in adults, with or without compensated cirrhosis. People with decompensated cirrhosis take it with ribavirin.
It does not treat hepatitis B, HIV, or liver cancer. Your doctor confirms your genotype and liver status before choosing the regimen.
References
Gilead Sciences. EPCLUSA (sofosbuvir and velpatasvir) tablets and oral pellets, US prescribing information, revised 04/2022.
Hetero. Hetero receives DCGI approval for generic sofosbuvir and velpatasvir (Velasof), press release, 5 May 2017.
Daily Excelsior. Hetero gets DCGI nod for generic chronic hepatitis C drug, 5 May 2017.
myUpchar. Velasof tablet listing, Hetero Drugs Ltd, strip of 28.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)